bioRxivNeurosciencePreprint
α-synuclein aggregates induce c-Abl activation and neurodegeneration by a redox stress mechanism
Soumitra GhoshiD, Seok Joon WoniD, Rebecca FongiD, Nicholas J. M. Butler, Arianna S MossiD, Candance Wong, June Pan, Jennifer Sanchez, Long WuiD, Jiejie WangiD, Fredric P. ManfredssoniD, Raymond A. SwansoniD
Abstract
ObjectiveRedox stress, c-Abl activation, and -synuclein aggregates each independently contribute to neurodegeneration in Parkinsons disease. Interactions between these factors may underlie convergent and feed-forward mechanisms of disease progression. Methods-synuclein aggregate formation was induced in neuronal cultures and mouse substantia nigra by exposure to pre-formed human -synuclein fibrils or by AAV-mediated over-expression of -synuclein. Aggregate formation, c-Abl activation, redox stress, and neurodegeneration were evaluated by immunohistochemistry and Western blots, and mouse motor function was evaluated using the rota-rod and pole tests. To suppress redox stress, cultures and mice were treated with N-acetyl cysteine, a thiol repletion agent that supports neuronal glutathione metabolism. ResultsIn primary neuron cultures, the formation of -synuclein aggregates led to redox stress and c-Abl activation. Redox stress alone, in the absence of -synuclein aggregates, was also sufficient to induced c-Abl activation. N-acetyl cysteine suppressed redox stress, and likewise suppressed both c-Abl activation and -synuclein aggregation. A similar pattern was observed in the two mouse models of Parkinsons disease. In both models, -synuclein aggregates in the substantia nigra were accompanied by redox stress, c-Abl activation, dopaminergic neurodegeneration and motor impairment, all of which were attenuated in mice treated with oral N-acetyl cysteine. InterpretationThese results indicate that -synuclein aggregates induce c-Abl activation by a redox stress mechanism. c-Abl in turn promotes -synuclein aggregation, and this potentially feed-forward process can be blocked by N-acetyl cysteine. The findings thus add mechanistic support for N-acetyl cysteine as a therapeutic for Parkinsons disease.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- N-terminal acetylation reduces α-synuclein pathology in models of Parkinson's disease
Esther del Cid‐Pellitero, Thomas Goiran, … Edward A. Fon·Neurobiology of DiseasePeer-reviewed·Jun 11, 2026
- A Novel Mouse Model of Parkinson's Disease for Investigating Progressive Pathology and Neuroprotection
Santhosh Kumar Subramanya, Shreshth Shekhar, … Poonam Singh Thakur·bioRxiv·Feb 13, 2025
- Fibrillar α-synuclein induces neurotoxic astrocyte activation via RIP kinase signaling and NF-κB
Tsui-Wen Chou, Nydia P. Chang, … Brian P. Daniels·Cell Death and DiseasePeer-reviewed·Jul 31, 2021
- Infection and herbicide exposure implicate c-Abl kinase in α-Synuclein Ser129 phosphorylation
Marzieh Ehsani, Zeyang Sun, … Thomas F. Meyer·Cell Communication and SignalingPeer-reviewed·Sep 23, 2025
- Can the lack of fibrillar form of alpha-synuclein in Lewy bodies be explained by its catalytic activity?
I. A. Kuznetsov, A. V. Kuznetsov·bioRxiv·May 9, 2021
- Knockout of Rab27b exacerbates neuropathology in alpha-synuclein mouse models
Kasandra Scholz, Mary A. Gannon, … Talene A. Yacoubian·Acta Neuropathologica CommunicationsPeer-reviewed·May 12, 2026